PrecisemAb Biotech is pleased to announce a technology licensing collaboration with GlycoNex to develop next-generation anti-glycan antibody drugs for solid tumors. Under this agreement, GlycoNex will adopt PrecisemAb’s Universal Antibody Lock technology, which keeps antibodies inactive in healthy tissues and enables selective activation by tumor-associated proteases.
By integrating PrecisemAb’s UAL platform with GlycoNex’s anti-glycan antibodies, the partnership aims to enhance tumor specificity, reduce on-target/off-tumor side effects, and improve overall therapeutic outcomes.
“We are honored to collaborate with GlycoNex in advancing innovative cancer therapies,” said Dr. Yun-Chu Lu, Chairman of PrecisemAb. “The Universal Antibody Lock technology is designed to offer patients safer and more precise treatment options.”
Invented by the late Professor Tien-Lu Cheng at Kaohsiung Medical University and exclusively licensed to PrecisemAb, the UAL technology can be broadly applied to monoclonal antibodies, ADCs, and bispecific antibodies, and is protected by patents in 18 countries.
PrecisemAb remains committed to enabling safer, smarter antibody therapeutics and accelerating the translation of breakthrough technologies into impactful treatments for patients worldwide.
SOURCE:
Pharma shot
